Perceptive Advisors
Latest statistics and disclosures from Perceptive Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, SYRE, CELC, ASND, RYTM, and represent 29.98% of Perceptive Advisors's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$310M), Kardigan Ord (+$196M), Avalyn Pharma (+$88M), RLAY (+$82M), TNGX (+$80M), BIIB (+$60M), RVMD (+$50M), UNH (+$49M), SYRE (+$48M), XBI (+$48M).
- Started 28 new stock positions in NVCT, UNH, Research Alliance Corp Iii, SLS, OTLK, MIRM, BSX, OSCR, KPRX, NAMS.
- Reduced shares in these 10 stocks: Ascendis Pharma A S (-$350M), Centessa Pharmaceuticals (-$209M), DYN (-$44M), Engene Holdings (-$40M), GH (-$39M), DAWN (-$38M), ABVX (-$34M), APGE (-$31M), PTGX (-$31M), DRUG (-$28M).
- Sold out of its positions in Apellis Pharmaceuticals, Ascendis Pharma A S, BLTE, DRUG, Centessa Pharmaceuticals, DAWN, Engene Holdings, EVMN, IKT, NMRA. NBIX, OCUL, IRD, PTN.
- Perceptive Advisors was a net buyer of stock by $506M.
- Perceptive Advisors has $6.7B in assets under management (AUM), dropping by 30.18%.
- Central Index Key (CIK): 0001224962
Tip: Access up to 7 years of quarterly data
Positions held by Perceptive Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Perceptive Advisors
Perceptive Advisors holds 108 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 10.2 | $682M | 2.0M | 334.79 |
|
|
| Spyre Therapeutics Com New (SYRE) | 5.8 | $384M | +14% | 4.3M | 88.78 |
|
| Celcuity (CELC) | 5.0 | $335M | +2% | 3.2M | 104.62 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 4.7 | $310M | NEW | 1.2M | 266.72 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.3 | $287M | +8% | 2.6M | 111.03 |
|
| Roivant Sciences SHS (ROIV) | 4.3 | $286M | -2% | 8.1M | 35.39 |
|
| Relay Therapeutics (RLAY) | 4.0 | $264M | +44% | 14M | 18.71 |
|
| Travere Therapeutics (TVTX) | 3.2 | $213M | -9% | 3.8M | 56.81 |
|
| Kardigan Ord | 2.9 | $196M | NEW | 8.2M | 23.85 |
|
| Nuvalent Inc-a (NUVL) | 2.9 | $195M | 1.6M | 123.50 |
|
|
| Edgewise Therapeutics (EWTX) | 2.7 | $178M | 4.4M | 40.63 |
|
|
| Apogee Therapeutics (APGE) | 2.6 | $174M | -15% | 1.3M | 132.73 |
|
| Amylyx Pharmaceuticals (AMLX) | 2.2 | $150M | 8.3M | 17.96 |
|
|
| Meiragtx Holdings (MGTX) | 2.2 | $146M | +4% | 11M | 13.51 |
|
| Oruka Therapeutics (ORKA) | 1.9 | $128M | -3% | 1.3M | 95.17 |
|
| Inhibrx Biosciences (INBX) | 1.8 | $123M | -10% | 1.3M | 94.75 |
|
| Protagonist Therapeutics (PTGX) | 1.8 | $120M | -20% | 982k | 122.58 |
|
| Solid Biosciences Com New (SLDB) | 1.8 | $119M | 12M | 9.99 |
|
|
| Zymeworks Del (ZYME) | 1.6 | $109M | +19% | 4.2M | 26.14 |
|
| Tango Therapeutics (TNGX) | 1.6 | $106M | +317% | 3.4M | 31.26 |
|
| Immatics SHS (IMTX) | 1.6 | $105M | 10M | 10.13 |
|
|
| Nurix Therapeutics (NRIX) | 1.6 | $105M | +16% | 4.3M | 24.26 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.5 | $103M | +38% | 10M | 10.00 |
|
| Revolution Medicines (RVMD) | 1.5 | $99M | +104% | 528k | 187.28 |
|
| Avalyn Pharmaceuticals Com Shs | 1.3 | $88M | NEW | 2.7M | 32.92 |
|
| Moderna Put Option (MRNA) | 1.1 | $70M | 1.0M | 70.03 |
|
|
| Dyne Therapeutics (DYN) | 0.9 | $60M | -42% | 2.7M | 22.21 |
|
| Biogen Idec (BIIB) | 0.9 | $60M | NEW | 276k | 216.06 |
|
| Immunovant (IMVT) | 0.8 | $52M | -15% | 1.4M | 38.53 |
|
| UnitedHealth (UNH) | 0.7 | $49M | NEW | 117k | 415.63 |
|
| Spdr Series Trust St Str Sp Biot Put Option (XBI) | 0.7 | $48M | NEW | 300k | 158.25 |
|
| Ionis Pharmaceuticals (IONS) | 0.7 | $45M | +12% | 566k | 79.29 |
|
| Sutro Biopharma Com Shs (STRO) | 0.7 | $43M | +82% | 1.3M | 33.20 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.6 | $43M | -19% | 1.6M | 26.39 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.6 | $41M | 170k | 240.97 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.6 | $40M | +16% | 2.7M | 14.94 |
|
| Sionna Therapeutics (SION) | 0.6 | $40M | +37% | 905k | 43.99 |
|
| Cytomx Therapeutics (CTMX) | 0.6 | $39M | +3% | 10M | 3.75 |
|
| CryoLife (AORT) | 0.6 | $39M | +6% | 1.7M | 22.47 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.6 | $37M | +17% | 7.9M | 4.67 |
|
| Capricor Therapeutics Com New Call Option (CAPR) | 0.5 | $36M | NEW | 1.5M | 24.08 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.5 | $35M | +696% | 398k | 86.95 |
|
| Repligen Corporation (RGEN) | 0.5 | $34M | -11% | 248k | 136.44 |
|
| Anteris Technologies Global (AVR) | 0.5 | $34M | 3.4M | 9.85 |
|
|
| Rapport Therapeutics (RAPP) | 0.5 | $32M | +14% | 773k | 41.67 |
|
| Damora Therapeutics Com New (DMRA) | 0.5 | $32M | 1.2M | 26.01 |
|
|
| Charles River Laboratories (CRL) | 0.5 | $32M | NEW | 140k | 226.79 |
|
| Axsome Therapeutics (AXSM) | 0.4 | $29M | -21% | 119k | 244.77 |
|
| Eyepoint Com New Put Option (EYPT) | 0.4 | $29M | NEW | 2.0M | 14.30 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 0.4 | $27M | +71% | 1.7M | 16.40 |
|
| Irhythm Technologies (IRTC) | 0.4 | $27M | +113% | 224k | 118.95 |
|
| Adaptive Biotechnologies Cor (ADPT) | 0.4 | $26M | +698% | 1.2M | 21.45 |
|
| Sab Biotherapeutics Com New (SABS) | 0.4 | $26M | +3% | 6.6M | 3.90 |
|
| Danaher Corporation (DHR) | 0.4 | $25M | NEW | 130k | 190.48 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $25M | +17% | 1.7M | 14.55 |
|
| Sellas Life Sciences Group I Com New Put Option (SLS) | 0.3 | $22M | NEW | 1.5M | 14.76 |
|
| Nautilus Biotechnology (NAUT) | 0.3 | $22M | -7% | 12M | 1.87 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.3 | $22M | 5.0M | 4.32 |
|
|
| Intuitive Surgical Com New (ISRG) | 0.3 | $21M | -39% | 52k | 397.68 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.3 | $21M | NEW | 1.8M | 11.50 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.3 | $21M | 1.3M | 16.39 |
|
|
| Nuvectis Pharma (NVCT) | 0.3 | $18M | NEW | 1.0M | 18.39 |
|
| Palisade Bio (PALI) | 0.3 | $18M | -5% | 8.4M | 2.09 |
|
| Omada Health (OMDA) | 0.3 | $17M | 786k | 21.95 |
|
|
| Athira Pharma (LONA) | 0.3 | $17M | 1.9M | 9.19 |
|
|
| Evolus (EOLS) | 0.3 | $17M | +91% | 2.5M | 6.94 |
|
| Newamsterdam Pharma Company Ordinary Shares Put Option (NAMS) | 0.3 | $17M | NEW | 500k | 33.89 |
|
| Adagio Therapeutics (IVVD) | 0.2 | $16M | -11% | 19M | 0.87 |
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.2 | $15M | 6.5M | 2.25 |
|
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $14M | NEW | 115k | 117.07 |
|
| Surrozen Com New (SRZN) | 0.2 | $13M | +119% | 504k | 25.95 |
|
| Beta Bionics (BBNX) | 0.2 | $13M | 833k | 15.67 |
|
|
| Axogen (AXGN) | 0.2 | $11M | -64% | 247k | 46.19 |
|
| Oscar Health Cl A (OSCR) | 0.2 | $11M | NEW | 400k | 28.52 |
|
| Oculis Holding Ordinary Shares (OCS) | 0.2 | $11M | +63% | 809k | 13.87 |
|
| Seaport Therapeutics Common Stock | 0.2 | $11M | NEW | 500k | 21.72 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $11M | -50% | 582k | 18.37 |
|
| Boston Scientific Corporation (BSX) | 0.2 | $11M | NEW | 250k | 42.68 |
|
| Billiontoone Cl A (BLLN) | 0.2 | $10M | -5% | 87k | 119.98 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.1 | $9.9M | -77% | 74k | 133.26 |
|
| Natera (NTRA) | 0.1 | $9.4M | NEW | 35k | 271.45 |
|
| Engene Therapeutics (ENGN) | 0.1 | $8.3M | NEW | 4.8M | 1.73 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.1 | $8.0M | NEW | 750k | 10.70 |
|
| Agomab Therapeutics Nv Sponsored Ads (AGMB) | 0.1 | $7.8M | 600k | 12.98 |
|
|
| Cullinan Oncology (CGEM) | 0.1 | $7.8M | NEW | 427k | 18.21 |
|
| Uniqure Nv SHS (QURE) | 0.1 | $7.7M | NEW | 168k | 46.06 |
|
| Mobia Med Common Stock | 0.1 | $7.0M | NEW | 524k | 13.40 |
|
| Adagio Med Hldgs (ADGM) | 0.1 | $6.4M | 9.9M | 0.65 |
|
|
| Guardant Health (GH) | 0.1 | $6.2M | -86% | 41k | 150.03 |
|
| Phathom Pharmaceuticals (PHAT) | 0.1 | $5.8M | -42% | 532k | 10.85 |
|
| Outlook Therapeutics (OTLK) | 0.1 | $5.0M | NEW | 3.1M | 1.59 |
|
| Cogent Biosciences (COGT) | 0.1 | $4.7M | 121k | 38.70 |
|
|
| Edesa Biotech Com New (EDSA) | 0.1 | $4.6M | 563k | 8.13 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $4.1M | +57% | 220k | 18.48 |
|
| Twist Bioscience Corp (TWST) | 0.1 | $3.8M | -75% | 37k | 102.88 |
|
| Crescent Biopharma (CBIO) | 0.1 | $3.7M | 207k | 18.00 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.1 | $3.7M | NEW | 467k | 7.92 |
|
| Outset Med Com New (OM) | 0.1 | $3.6M | 833k | 4.32 |
|
|
| Biodesix (BDSX) | 0.0 | $2.5M | NEW | 109k | 22.55 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $2.3M | 250k | 9.38 |
|
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.0 | $1.9M | 793k | 2.38 |
|
|
| Kiora Pharmaceuticals (KPRX) | 0.0 | $1.2M | NEW | 439k | 2.63 |
|
| Medline Com Cl A (MDLN) | 0.0 | $1.1M | 28k | 39.44 |
|
|
| Adma Biologics (ADMA) | 0.0 | $952k | -75% | 114k | 8.37 |
|
| Cumberland Pharmaceuticals (CPIX) | 0.0 | $628k | -50% | 97k | 6.48 |
|
| Exagen (XGN) | 0.0 | $534k | 115k | 4.65 |
|
|
| Ensysce Biosciences Com New (ENSC) | 0.0 | $25k | 87k | 0.29 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $2.7k | 167k | 0.02 |
|
Past Filings by Perceptive Advisors
SEC 13F filings are viewable for Perceptive Advisors going back to 2010
- Perceptive Advisors 2026 Q2 filed Aug. 14, 2026
- Perceptive Advisors 2026 Q1 restated filed May 29, 2026
- Perceptive Advisors 2026 Q1 filed May 15, 2026
- Perceptive Advisors 2025 Q4 filed Feb. 17, 2026
- Perceptive Advisors 2025 Q3 filed Nov. 14, 2025
- Perceptive Advisors 2025 Q2 filed Aug. 14, 2025
- Perceptive Advisors 2025 Q1 restated filed Aug. 6, 2025
- Perceptive Advisors 2025 Q1 filed May 15, 2025
- Perceptive Advisors 2024 Q4 filed Feb. 14, 2025
- Perceptive Advisors 2024 Q3 filed Nov. 14, 2024
- Perceptive Advisors 2024 Q2 restated filed Aug. 16, 2024
- Perceptive Advisors 2024 Q2 filed Aug. 14, 2024
- Perceptive Advisors 2024 Q1 restated filed Aug. 6, 2024
- Perceptive Advisors 2024 Q1 filed May 15, 2024
- Perceptive Advisors 2023 Q4 restated filed Feb. 26, 2024
- Perceptive Advisors 2023 Q4 filed Feb. 14, 2024